IL-27 and type 2 immunity in asthmatic patients: Association with severity, CXCL9, and signal transducer and activator of transcription signaling
Year: 2014
Type: article
Study design: Observational Study
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Amgen, Pfizer, AstraZeneca, GlaxoSmithKline, Merck, National Natural Science Foundation of China, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences
Awards: G1134233510, Redox-Derived Pulmonary Anti-Inflammatory Mediators, G1333222402, G1475648229, Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma, G1812657964, G205448200, Amplification of IL-4Ralpha signaling pathways in human airways through 15 LO1, G2262667294, G2451186505, G2799981763, G2917626830, G3028257315, Inflammation of Myofibroblasts and Loss of Elastic Recoil in Severe Asthma, G3223375572, G3340006017, G3437871997, General Clinical Research Center, G3724172460, University of Pittsburgh Clinical and Translational Science Institute, Redox Transduction of Nitric Oxide Signaling, G4515727063, G466485952, Colorado Clinical and Translational Sciences Institute, G6026445463, G605541407, G619100720, G620260875, G6264781781, G6336038351, G653690408, Th2 effects on eicosanoid pathways: implications for altered innate responses in, G7312103647, G7769938532, G7975917069, G7978299309, G8055992094, Anti-Inflammatory Lipid Mediators in Asthma, G8372283077, G8682086711, G8801288690, Immune Airway-Epithelial Interactions in Steroid-Refractory Severe Asthma
OpenAlex ID: W2011828552